Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol

Leukemia

Volumn 23, Issue 3, 2009, Pages 594-596

  Zaher, M ^a,b,c   Akrout, I ^a,b,c   Mirshahi, M ^a,b,c   Kolb, J P ^a,b,c   Billard, C ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; FLAVOPIRIDOL; HYPERFORIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN BAK; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN NOXA;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; UPREGULATION;

EID: 62549116204     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.239     Document Type: Article

References (12)

1. Kolb JP, Kern C, Quiney C, Roman V, Billard C. Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Hematol Disord 2003; 3: 261-286.
2. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404.
3. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.
4. Quiney C, Billard C, Faussat AM, Salanoubat C, Ensaf A, Naït-Si Y et al. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 2006; 20: 491-497.
5. Quiney C, Billard C, Salanoubat C, Fourneron JD, Kolb JP. Hyperforin, a new lead compound against the progression of cancer and leukemia? Leukemia 2006; 20: 1519-1525.
6. Willis SN, Adams JM. Life in the balance: How BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17: 617-625.
7. Smit L, Hallaert DYH, Spijker R, de Goeij B, Jaspers A, Kater AP et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlate with survival capacity. Blood 2007; 109: 1660-1668.
8. kip1 in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17: 2345-2443.
9. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65: 6282-6293.
10. Pérez-Galan P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomid induces apoptosis in mantle-cell lymphome through generation of ROS and Noxa induction activation independent of p53 status. Blood 2006; 107: 257-264.
11. Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007; 21: 1773-1782.
12. Pérez-Galan P, Roué G, Lopez-Guerra M, Nguyen M, Villamor N, Montserrat E et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, e-pub ahead of print 3 July 2008; doi: 10.1038/leu.2008.175.